Table 1.

Baseline patient characteristics (n = 19).

Age (mean)	58.5
Hormone receptor status
ER−/PgR−	7 (36.8%)
ER+/PgR−	5 (26.3%)
ER−/PgR+	1 (5.2%)
ER+/PgR+	6 (31.6%)
Previous therapy for metastatic disease
No prior therapy	2 (10.5%)
1 line of treatment	1 (5.2%)
2 lines of treatment	7 (36.8%)
⩾3 lines of treatment	9 (47.4%)
Median no. of lines	2.5 (0–11)
ECOG performance status
0	4 (21.1%)
1	12 (63.2%)
2	3 (15.8%)
Median # of CNS progressions prior to study (range)	2 (0–5)
Measurable extra-CNS disease at baseline	8 (42.1%)

CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; PgR, progesterone receptor.